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doi:10.1Objective: Aortic surgical procedures requiring hypothermic circulatory arrest are associated with altered he-
mostasis and increased bleeding. In a randomized clinical trial, we evaluated effects of thromboelastometrically
guided algorithm on transfusion requirements.
Methods: Fifty-six consecutive patients (25 with acute type A dissection) undergoing aortic surgery with
hypothermic circulatory arrest were enrolled in a randomized trial during a 6-month period. Patients were
randomly allocated to treatment group (n ¼ 27) with thromboelastometrically guided transfusion algorithm
or control group (n ¼ 29) with routine transfusion practices (clinical judgment–guided transfusion followed
by transfusion according to coagulation test results). Primary end point was cumulative allogeneic blood units
(red blood cells, fresh-frozen plasma, and platelets) transfused.
Results: Transfusion of allogeneic blood was significantly reduced in the thromboelastometry group: median
9.0 units (interquartile range, 2.0–30.0 units) versus. 16.0 units (9.0–23.0 units, P ¼ .02). Most significant
decrease was in the use of fresh-frozen plasma (3.0 units, 0–12.0 units, vs 8.0 units, 4.0–18.0 units,
P ¼ .005). Postoperative blood loss (890 mL/d, 600–1250 mL/d vs 950 mL/d, 650–1400 mL/d, p ¼ 0.5) and
rate of surgical re-exploration (19% vs 24%, P ¼ .7) were similar between groups. Thromboelastometrically
guided algorithm significantly decreased need for massive perioperative transfusion (odds ratio, 0.45; 95%
confidence interval, 0.2–0.9; P ¼ .03) in multivariable logistic regression analysis.
Conclusions: Thromboelastometrically guided transfusion is associated with a decreased use of allogeneic
blood units and reduced incidence of massive transfusion in patients undergoing aortic surgery with circulatory
arrest. (J Thorac Cardiovasc Surg 2010;140:1117-24)P
MSupplemental material is available online.
Aortic surgical procedures requiring hypothermic circulatory
arrest (HCA) are associated with altered hemostasis and in-
creased bleeding.1,2 Multiple factors have been reported to
cause hemostatic derangements after aortic surgery,
including surgical trauma, hypothermia, ischemia–
reperfusion injury, extensive blood product and fluid
requirements, activation of the systemic inflammatory
response and fibrinolysis, and prolonged use of
cardiopulmonary bypass (CPB).3-7 These interactions can
result in massive blood loss after aortic surgical procedures,e Departments of Cardiac Surgerya and Anesthesiology/Intensive Care,b
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The Journal of Thoracic and Carwhich in turn is associated with an 8-fold increase in in-
hospital mortality.8 The multifactorial nature of coagulation
disorders complicates clinical management, and treatment
is often empirical.9
The positive effects of transfusion algorithms and point-
of-care hemostasis testing on postoperative blood loss and
transfusion requirements have been reported in several stud-
ies.10-13 Reagent-modified rotational thromboelastometry
(ROTEM) has an advantage of functional testing for spe-
cific defects in coagulation, all of which have specific treat-
ment possibilities currently available to the practitioner. We
wanted to determine whether a ROTEM-guided transfusion
protocol would benefit patients undergoing high-risk aortic
surgery. We therefore performed a monocentric, prospec-
tive study to compare transfusion requirements in patients
undergoing aortic surgery with HCA and randomly allo-
cated to receive either a ROTEM-guided transfusion proto-
col or standard clinical care.MATERIALS AND METHODS
Patients
Approval for the study was obtained from the ethics committee of
University Leipzig (Reg. No. 151-2007), and all patients gave written,
informed consent. Eligible patients were those older than 18 years under-
going aortic surgery requiring HCA, including urgent and emergency sur-
gery. Excluded patients were those who were pregnant, had knowndiovascular Surgery c Volume 140, Number 5 1117
TABLE 1. Transfusion protocol in the thromboelastometrically
guided transfusion group
Finding Response
CT by HEPTEM>260 s FFP (15 mL/kg body mass)
CT by APTEM>120 s 3000 IU PPSB
MCF by HEPTEM 35–45 mm,
MCF by FIBTEM>8 mm
1 platelet concentrate
MCF by HEPTEM<35 mm 1 platelet concentrate
MCF by FIBTEM<8 mm 2 g fibrinogen
MCF by APTEM/MCF by HEPTEM>1.5 3 g tranexamic acid
CT by INTEM/CT by HEPTEM>1.5
(in any post-CPB analysis)
5000 IU protamine
Protocol lists actions taken in response to findings of 4-channel rotational thromboe-
lastometric analysis at 32C rectally. CT, Coagulation time; HEPTEM, intrinsic acti-
vation plus heparinase neutralization thromboelastometry; FFP, fresh-frozen plasma;
APTEM; extrinsic activation plus aprotinin thromboelastometry; PPSB, prothrombin
complex concentrate; MCF, maximal clot firmness; FIBTEM, fibrinogen-based ex-
trinsic activation thromboelastometry; INTEM, intrinsic activation thromboelastom-
etry; CPB, cardiopulmonary bypass.
TABLE 2. Transfusion protocol in the control group
Finding Response
Activated clotting time>160 s 5000 IU protamine (1 time)
Partial thromboplastin time
>60 s or INR>1.5
FFP (15 mL/kg body mass)*
Platelets<100,000 cells/mL 1 platelet concentrate
Fibrinogen<1.2 mg/dL 2 g fibrinogen
a2-Antiplasmin<80% 3 g tranexamic acid
Protocol lists actions taken in response to results of standard coagulation tests (plate-
let count, international normalized ratio, partial thromboplastin time, fibrinogen, a2-
antiplasmin, activated clotting time, antithrombin III) after protamine administration.
FFP, Fresh-frozen plasma; INR, international normalized ratio. *Give 3000 IU pro-
thrombin complex concentrate only if international normalized ratio greater than
2.0 along with known liver dysfunction or warfarin therapy.
Abbreviations and Acronyms
ACT ¼ activated clotting time
HCA ¼ hypothermic circulatory arrest
ICU ¼ intensive care unit
RBC ¼ red blood cell
ROTEM ¼ rotational thromboelastometry
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M(inherited) coagulation disorders (hemophilia A or B, activated protein C
resistance, etc), or were unable to give informed consent. Patients receiving
preoperative antiplatelet or anticoagulant therapy were eligible to partici-
pate. A total of 56 patients were entered into the trial between July 2007
and January 2008. Patients were randomly assigned with a computer-
generated randomization list to either of 2 study groups: a control group
(intraoperative transfusion guided by clinical judgment, followed by trans-
fusion according to routine coagulation tests, n ¼ 29) and a treatment
group (ROTEM-guided transfusion algorithm, n ¼ 27). Both transfusion
algorithms are described in further detail (Tables 1 and 2). Random
assignment was performed immediately on enrollment in the study.
Study End Points
The primary end point of the study was the cumulative number of allo-
geneic blood units (red blood cells [RBCs], fresh-frozen plasma, and plate-
lets) transfused per patient. Secondary outcome measures were the use of
prothrombin complex concentrate, fibrinogen concentrate, and recombi-
nant factor VIIa (NovoSeven; Novo Nordisk A/S, Bagsværd, Denmark),
blood losses in the first 12 and 24 postoperative hours, incidence of surgical
re-exploration for bleeding, and related clinical outcome parameters (time
to extubation, neurologic and renal complications, and stay in the intensive
care unit [ICU]).
Intraoperative Management
Systemic full-dose heparin (300 units/kg) was administered as a bolus
before cannulation for CPB. The activated clotting time (ACT) determined
with Celite (Celite Corporation, Santa Barbara, Calif) was checked every
20 minutes during CPB, and additional heparin (5000 units) was given
when the ACT was less than 450 seconds. Tranexamic acid was routinely
used in both study arms according to a standardized protocol: 1 g intrave-
nous infusion after anesthetic induction, 1 g intravenous infusion after skin
incision, 1 g into the pump prime, and 1 g/h after discontinuation of CPB
until the end of procedure.
CPB was instituted with right axillary perfusion and right atrial venous
drainage. Systemic cooling was carried out with a maximal temperature
gradient of 6C. Directly before systemic perfusion was stopped, ice packs
were placed around the head, and 100mg dexamethasonewas administered
intravenously. Any aortic root procedure necessary was performed during
the cooling phase. HCA was induced once the systemic temperature
reached 23C to 25C rectally. Antegrade cerebral perfusion (10 mL/]kg
$ min]) was applied through perfusion of the axillary artery during clamp-
ing of the brachiocephalic trunk or direct cannulation of the supra-aortic
vessels. Distal aortic repair was performed with an open technique during
HCA. Perfusion was restored and rewarming was initiated thereafter, with
a temperature gradient of less than 6C. Rewarming was discontinued once
the rectal temperature reached 36C.
After discontinuation of CPB, reversal of heparin with a protamine ratio
of 1:1 (1 mg \protamine per 100 units total heparin) was performed. An in-
traoperative cell-salvage device with reinfusion of shed mediastinal blood
was used in all cases. No platelet-augmenting therapy, such as desmopres-
sin acetate, was used. The only colloid used was 6% hydroxyethyl starch in
a 130/0.4 solution.1118 The Journal of Thoracic and Cardiovascular SurTriggers for RBC transfusion were identical in both study arms: a min-
imum hematocrit of 20% (hemoglobin 6.8 g/dL) during CPB and a mini-
mum hematocrit of 25% (hemoglobin 8.5 g/dL) after CPB. RBCs were
occasionally transfused despite hematocrit levels greater than 25% when
physiologic transfusion triggers occurred: hemodynamic instability (epi-
nephrine or norepinephrine>10 mg/[kg $min]), signs of myocardial ische-
mia on electrocardiography, or drop in mixed venous oxygen saturation
below 50% (central venous oxygen saturation below 60%). Mixed venous
oxygen saturation was measured with a pulmonary artery catheter only in
patients who required high-dose catecholamine support (epinephrine or
norepinephrine,>10 mg/[kg $ min]) to wean them from CPB or who had
low cardiac output later in the ICU. The remaining patients were monitored
with only central venous oxygen saturation measurements.
Hemostatic Management
ROTEM group. Intraoperative and postoperative transfusions of
blood products were guided by a ROTEM-based protocol (Table 1).
Reagent-modified 4-channel rotational thromboelastometry with ROTEM
coagulation analyzer (Matel Medizintechnik GmbH, Munich, Germany)
was implemented to screen for coagulation disorders. The basic principles
of ROTEM have been previously described in multiple studies.14-18 Briefly,
the original thrombelastometric procedure has been modified by providing
computerized analysis of the trace and by adding different coagulation-
accelerating agents to make the analysis more expeditious and to allow
the detection of specific coagulation defects (factor deficiency, presence of
heparin, fibrinogen deficiency, platelet deficiency, and hyperfibrinolysis).gery c November 2010
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MThe 2 treatment-relevant parameters of the ROTEM trace (used in this study)
are clotting time, which allows the analysis of coagulation factor deficiency
or presence of anticoagulants, and maximal clot firmness, which gives infor-
mation about fibrinogen and platelets (Figure E1). A baseline test (INTEM)
uses a contact activator to analyze the general coagulation status related to in-
trinsic factors. In a simultaneously performed intrinsic clotting test with
added heparinase (HEPTEM), residual heparin can be demonstrated. In
a test of extrinsic factors (FIBTEM), cytochalasin D is used as a platelet in-
hibitor, allowing the analysis of fibrinogen effect on maximal clot firmness
alone. In another test of extrinsic factors (APTEM), tissue factor and aproti-
nin are used to identify hyperfibrinolysis. The 4measurement channels of the
ROTEMdevice allow performance of all 4 tests simultaneouslywith a single
analyzer run.
Initial ROTEM analysis was performed at 32C during the rewarming
phase of CPB. Test results were available for operating room personnel be-
fore to the beginning of weaning from CPB, approximately 20 to 25 min-
utes after blood sampling. The required blood products were ordered
according to the appropriate transfusion protocol (Table 1) and adminis-
tered simultaneously with protamine infusion after discontinuation of
CPB. The extent of microvascular bleeding was assessed subjectively by
the attending surgeon as the absence of visible clots in the surgical field
15 minutes after administration of blood products. The second ROTEM
analysis was carried out for documentation of transfusion effect, irrespec-
tive of bleeding. If no microvascular bleeding was determined, the chest
was closed, and further ROTEM tests were performed in the ICU only in
case of increased bleeding (>200 mL in the first hour or>100 mL/h there-
after). Further blood products were given according to the results of RO-
TEM analysis. In cases of persistent microvascular bleeding in the
operating room, ROTEM coagulation analysis was performed 15 minutes
after administration of all appropriate coagulation products, and new blood
products were ordered according to the results of the most recent analysis.
Control group. Patients in the control group received the initial trans-
fusion in the operating room on the basis of clinical judgment (empirically)
and subsequently on the basis of standard coagulation test results (Table 2).
This protocol was the same as that we had previously used for routine clin-
ical practice in patients undergoing aortic surgery with HCA. After discon-
tinuation of CPB, protamine was administered simultaneously with other
blood products, as the attending anesthesiologist and operating surgeon
deemed them necessary. One additional dose of protamine (50 mg) was
given if the postprotamine ACT had not returned to within 15% of the pre-
heparin value. Blood samples for laboratory tests were drawn thereafter. If
no abnormal bleeding was observed, the chest was closed, and further
transfusion was performed only in case of increased bleeding in the ICU
(>200 mL in the first hour or>100 mL/h thereafter), according to the algo-
rithm based on coagulation test results (Table 2). In cases of persistent ooz-
ing with no visible clots in the operating field, further blood products were
administered on an empirical basis until coagulation test results were avail-
able. An interval of approximately 60 minutes was required to receive the
results from the laboratory.
Management in the ICU. Surgical re-explorationwas performed if
bleeding persisted despite normal ROTEM analysis (ROTEM group) or co-
agulation test results (control group), if bleeding was excessive (>400 mL/
h), or if signs of cardiac tamponade occurred. The criteria for surgical re-
exploration were identical in both study arms. The decision for off-label
use of recombinant factor VIIa (NovoSeven) was made if the bleeding per-
sisted after resternotomy without any identifiable surgical bleeding source.
A dose of 80 mg/kg was administered, irrespective of group affiliation.
Statistical Analysis
Power analysis was based on our initial experiencewith the ROTEM an-
alyzer and the results from previous studies with thromboelastometrically
guided algorithms in cardiac surgery.16,18 Power analysis suggested that 30
patients per group would be required to demonstrate a 40% reduction in the
use of allogeneic blood products at an a of 0.05 and a power of 80%.The Journal of Thoracic and CarCategoric variables are expressed as percentages, and continuous vari-
ables are expressed as mean SD or as median with 25th and 75th percen-
tiles (interquartile range) throughout this article. All statistical analyses
were performed with the SPSS version 14.0 software package (SPSS Inc,
an IBM Company, Chicago, Ill). Continuous variables were analyzed
with the unpaired 2-tailed Student t test (after confirmation of normal dis-
tribution and homogeneity of variance by the Levene test) or with the
Mann–WhitneyU test for nonnormally distributed variables. Fisher’s Exact
test was applied to all categoric variables. All comparisons weremade on an
intention-to-treat basis. Logistic regression analysis was used to identify
predictors of massive transfusion (>20 units of allogeneic blood).RESULTS
A total of 56 consecutive patients were enrolled in the
study during a period of 6 months (from July 2007 to Janu-
ary 2008). Nearly all patients (33 of 35) undergoing elective
aortic surgery with HCA during the study period were en-
rolled. Two elective patients were not recruited because of
technical problems with the ROTEM analyzer at the time
of surgery. The decision to perform HCAwas made intrao-
peratively (was not planned on the basis of preoperative
evaluation) in another 3 elective cases during the study pe-
riod and these patients were not included in the study. A to-
tal of 31 patients with acute type A dissection were operated
on during the study period, and 25 of them (81%) were in-
cluded in this study. The reasons for nonenrollment in this
subgroup were critical patient status (written, informed con-
sent could not been obtained) in 4 cases and nonavailability
of the study personnel in the remaining 2 cases.
A total of 98 thromboelastometric analyses were per-
formed in the ROTEM group (3.6 tests/patient). Diver-
gences from the treatment algorithm were required in 4
patients (15%) in the ROTEM group and 2 patients (7%)
in the control group. Two patients with acute type A dissec-
tion in the ROTEM group had persistent microvascular
bleeding after the first administration of blood products ac-
cording to the ROTEM protocol, and further blood products
were ordered empirically on preference of the operating
surgeon. The third patient had a massive blood loss caused
by intraoperative dissection of the descending thoracic aorta
and underwent empirical transfusion therapy in the operat-
ing room. One elective patient in ROTEM group underwent
empirical transfusion because of the unavailability of RO-
TEM analysis results after discontinuation of CPB (RO-
TEM analysis had to be repeated because of inadequacy
of the first sample). Both treatment divergence patients in
the control group were operated on for acute type A dissec-
tion and required use of recombinant factor VIIa because of
persistent microvascular bleeding, despite numerous empir-
ical blood product transfusions. The results from all 6 pa-
tients were included on an intention-to-treat basis.
The 2 groups were similar with regard to preoperative
characteristics. In particular, the proportion of patients pre-
senting with acute dissection was not different between
groups (41% vs 48%, P ¼ .6; Table 3). There were nodiovascular Surgery c Volume 140, Number 5 1119
TABLE 3. Preoperative variables
Variable ROTEM (N ¼ 27) Control (N ¼ 29) P value
Age (y, mean  SD) 63.5  13.5 59.9  17.5 .3
Male (no.) 15 (56%) 17 (59%) .8
Body mass index (kg/m2, mean  SD) 27.1  8.0 27.4  4.5 .9
Arterial hypertension (no.) 22 (82%) 22 (76%) .7
Left ventricular ejection fraction (%, mean  SD) 57.2%  11.6% 62.7%  13.5% .2
Peripheral arterial disease (no.) 1 (4%) 1 (4%) .9
Chronic obstructive pulmonary disease (no.) 4 (15%) 3 (10%) .6
Liver dysfunction (no.) 1 (4%) 2 (7%) .7
Diabetes mellitus (no.) 4 (15%) 3 (10%) .6
Preoperative creatinine (mg/dL, mean  SD) 0.9  0.3 1.1  0.4 .2
Preoperative shock (no.) 1 (4%) 1 (4%) .9
Acute type A aortic dissection (no.) 11 (41%) 14 (48%) .6
Chronic aortic dissection (no.) 4 (15%) 5 (17%) .8
Nondissecting aortic aneurysm (no.) 12 (44%) 10 (35%) .5
Marfan syndrome (no.) 4 (15%) 4 (14%) .9
Previous cardiac surgery (no.) 5 (19%) 7 (24%) .7
Preoperative aspirin (no.) 9 (33%) 8 (28%) .5
Preoperative warfarin (no.) 1 (4%) 1 (4%) .9
Preoperative hematocrit (%, mean  SD) 38.0%  5.0% 36.9%  6.5% .6
Preoperative hemoglobin (g/dL, mean  SD) 12.6  1.9 12.2  2.5 .6
Platelet count (cells/mL, mean  SD) 220  90 245  110 .6
International normalized ratio (mean  SD) 1.3  0.6 1.1  0.4 .8
Partial thromboplastin time (s, mean  SD) 37  14 39  11 .8
Fibrinogen (mg/dL, mean  SD) 2.2  1.7 2.4  2.0 .9
a2-Antiplasmin (%, mean  SD) 92%  7.0% 94%  9.5% .8
Activated clotting time (s, mean  SD) 145  90 136  80 .6
Logistic EuroSCORE (%, mean  SD) 30.7%  20.3% 28.6%  16.6% .7
ROTEM, Thromboelastometry.
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Mmajor differences in the use of aspirin and warfarin before
surgery, and none of the patients were receiving preopera-
tive clopidogrel or heparin. A total of 79% of patients in
the control group and 82% of patients in the ROTEM group
(P ¼ .8) were classified as having high-risk score for mas-
sive perioperative transfusion, according to the published
transfusion risk scores.19,20
The details of intraoperative management are displayed
in Table 4. The extent of surgical procedurewas comparable
between the groups, although there was a trend toward
slightly longer CPB and aortic crossclamp times, as well
as higher incidence of aortic root replacement, in the control
group. None of these differences, however, reached statisti-
cal significance.
The primary and secondary outcomes are displayed in
Table 5. The cumulative use of allogeneic blood unitswas re-
duced by 44% in the ROTEM group relative to the control
group (9.0 units, 2.0–30.0 units, vs 16.0 units, 9.0–23.0 units,
P¼ .02). The most significant decrease was achieved in the
use of fresh-frozen plasma. Although there was a significant
difference in RBC transfusion between the groups until 24
hours postoperatively (Figure E2), there was only a trend to-
ward a reduced cumulative RBC transfusion for the whole
hospital stay (Table 5). The transfusion requirements
for platelets and fibrinogen concentrate were comparable1120 The Journal of Thoracic and Cardiovascular Surbetween groups. The use of prothrombin complex concen-
trate was significantly reduced in the ROTEM-guided group
(Table 5). Recombinant factor VIIa was used in 1 patient
(4%) in the ROTEM group versus 2 patients (7%) in the
control group (P ¼ .8).
Blood losses in the first 12 and 24 postoperative hours
and the need for surgical re-exploration for bleeding were
similar between groups. A surgical bleeding source was
identified in most of the re-explored patients (80% of re-
explored patients in the ROTEM group vs 71% in the con-
trol group).
Hemoglobin levels were comparable between the groups
throughout the postoperative course: 9.4  1.5 g/dL in the
ROTEM group versus 9.2  0.9 g/dL in the control group
(P¼ .7) at arrival in the ICU, 9.6 0.6 g/dL in the ROTEM
group versus 9.1 0.7 g/dL in the control group (P¼ .4) at
24 postoperative hours, and 10.7 2.3 g/dL in the ROTEM
group versus 10.3 1.6 g/dL in the control group (P¼ .6) at
discharge from the hospital.
Clinical outcome variables were comparable between
groups. In particular, there were no differences in the inci-
dencesof respiratory insufficiency, neurologic complications,
and dialysis-dependent renal failure. Accordingly, the ICU
stay, hospital stay, and in-hospital mortality were similar
between groups (Table E1).gery c November 2010








Axillary arterial perfusion (no.) 18 (67%) 20 (69%) .8
Cardiopulmonary bypass
(min, mean  SD)
196.5  50 208  52 .3
Aortic crossclamp (min, mean  SD) 101.7  22 115.9  37 .2
Circulatory arrest (min, mean  SD) 22.3  18 25.8  23 .5
Minimal temperature (C, mean  SD) 24.5  1.6 24.8  3.5 .8
Antegrade cerebral perfusion (no.) 22 (82%) 23 (79%) .8
Aortic root replacement (no.) 11 (41%) 16 (55%) .1
Aortic root reconstruction (no.) 12 (44%) 9 (31%) .2
Hemiarch replacement (no.) 16 (59%) 15 (52%) .5
Total arch replacement (no.) 10 (37%) 12 (41%) .8
Concomitant coronary artery
bypass grafting (No.)
3 (11%) 4 (14%) .8
ROTEM, Thromboelastometry.
Girdauskas et al Perioperative ManagementIn a subgroup analysis of 16 elective patients in the RO-
TEM group, 4 patients did not need any blood products
transfused. None of the patients in the control group
avoided allogeneic blood transfusion. Four patients with di-
vergences from the transfusion protocol in the ROTEM
group required massive perioperative transfusion (a total
of 114 allogeneic blood units, 38% of all units used in
the ROTEM group).
We conducted a logistic regression analysis to identify
the predictors of massive transfusion (>20 allogeneic blood
units). A total of 9 clinically relevant variables were in-
cluded in the multivariate model, and the ROTEM-guidedTABLE 5. Perioperative transfusion and blood loss
Variable ROTEM
RBCs (units, median and IQR) 6.0 (2.
Patients transfused with RBCs (no.) 24 (89
FFP (units, median and IQR) 3.0 (0–
Patients transfused with FFP (no.) 9 (33
Platelet concentrate (units, median and IQR) 1.0 (0–
Patients transfused with platelets (no.) 14 (52
Allogeneic blood units (cumulative, median and IQR) 9.0 (2.
Patients transfused with allogeneic blood (no.) 24 (89
PCC (IU, median and IQR) 0 (0–
Patients transfused with PCC (no.) 4 (15
Fibrinogen concentrate (g, median and IQR) 2.0 (2.
Patients transfused with fibrinogen (no.) 21 (78
Patients with massive transfusion (>20 units, no.) 5 (19
Blood loss in 12 h (mL, median and IQR) 600 (38
Blood loss in 24 h (mL, median and IQR) 890 (60
Re-exploration for bleeding (no.) 5 (19
Non-RBC fluid balance in OR (mL, median and IQR) 1800 (12
24-h non-RBC fluid balance (mL, median and IQR) 2600 (17
Total heparin dose (IU, median and IQR) 38,000 (32
Total protamine dose (IU, median and IQR) 41,000 (34
Use of factor VIIa (no.) 1 (4%
ROTEM, Thromboelastometry; RBC, red blood cell; IQR, interquartile range; FFP, fresh-
The Journal of Thoracic and Caralgorithmwas found to be protective againstmassive alloge-
neic blood product transfusion (odds ratio 0.45, P ¼ .03;
Table E2).
DISCUSSION
Several studies have advocated the benefits of ROTEM-
guided algorithms in terms of transfusion reduction in car-
diac surgical patients.17,18 Most of these studies, however,
have included elective coronary and valve surgical patients
at low or medium risk for perioperative bleeding.17,18,21,22
Therefore little is known about ROTEM-guided coagulation
management in cardiac surgical patients at high risk for
excessive bleeding. A review of the literature revealed
a single study that specifically addressed ROTEM-guided
transfusion in pediatric cardiac surgical patients undergoing
HCA (n ¼ 10).23 To the best of our knowledge, a ROTEM-
guided transfusion protocol has not been specifically
evaluated in adult patients undergoing aortic surgery with
HCA.
We performed a randomized trial comparing the effects
of ROTEM-guided coagulation management with those
of standard clinical care in patients undergoing aortic sur-
gery with HCA. We assumed that the major benefit of
heparinase-modified ROTEM would be an early identifica-
tion of coagulation abnormalities during the rewarming
phase of CPB, with subsequent administration of required
blood components (according to the ROTEM protocol)
simultaneously with protamine infusion.24 We anticipated
that this approach would save the maximum amount of
time, reduce the amount of shed mediastinal blood(N ¼ 27) Control (N ¼ 29) P value
0–13.0) 9.0 (4.0–14.0) .2
%) 27 (93%) .8
12.0) 8.0 (4.0–18.0) .01
%) 25 (86%) <.001
4.0) 2.0 (1.0–3.0) .7
%) 23 (79%) .03
0–30.0) 16.0 (9.0-23.0) .02
%) 29 (100%) .06
2000) 3000 (2000–3000) <.001
%) 26 (90%) <.001
0–3.0) 2.0 (2.0–3.0) .7
%) 26 (90%) .2
%) 10 (35%) .1
0–950) 680 (450–1000) .3
0–1250) 950 (650–1400) .5
%) 7 (24%) .7
00–2200) 1600 (1100–2000) .7
00–2900) 2500 (1500–3000) .8
,000–43,000) 39,000 (34,000–46,000) .8
,000–46,000) 43,000 (35,000–49,000) .6
) 2 (7%) .8
frozen plasma; PCC, prothrombin complex concentrate.
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Mreinfused, and stop the progression of coagulopathy at
a very early stage.
The main finding of this study is that a significant reduc-
tion in allogeneic blood transfusion was achieved by means
of a ROTEM-guided algorithm in patients undergoing aor-
tic surgery with HCA. In addition, ROTEM-guided coagu-
lation management was associated with a decreased risk of
massive transfusion, after adjustment for other important
transfusion risk factors (Table E2).
The observed cumulative decrease in allogeneic blood
unit use of 44% in the ROTEM group is in accordance
with the results of a previous randomized trial involving
cardiac surgical patients at low or medium risk for excessive
bleeding.24 We observed the most significant reduction in
the use of fresh-frozen plasma, which was decreased by
62% in the ROTEM group. Similar evidence comes from
another randomized trial in which the decrease in use of al-
logeneic blood products in the thrombelastometry group
was predominantly caused by a reduced need for fresh-
frozen plasma transfusion.21
In contrast, fibrinogen deficiency was one of the most
common findings of our ROTEM analyses. The key role
of fibrinogen substitution in major surgical bleeding has
been stressed in several previous publications.25
The use ofRBCunits in theROTEMgroup showed a 33%
decrease relative to that in the control group, although this
difference did not reach statistical significance. Other inves-
tigators have reported similar findings,18 although some
groups have found a statistically significant reduction in
RBC transfusions in their thromboelastometrically guided
transfusion groups.17,21 The prolonged and complicated
postoperative courses of more than 20% of the high-risk pa-
tients in our study necessitated transfusion of additional
RBC units later, during the ICU or intermediate care unit
stay. These late transfusions mitigated the initially statisti-
cally significant difference (Figure E2) between the study
groups. Moreover, the protocol violations in the cases of 4
patients in theROTEM-guided groupwho underwent empir-
ical blood product therapy and subsequently required mas-
sive transfusion (accounting for 38% of the allogeneic
blood units used in the ROTEM group) may have further re-
duced the difference in RBC use between the study groups.
The second most common finding in our ROTEM analy-
ses was quantitative or qualitative platelet deficiency. Al-
though the proportion of patients requiring transfusion of
platelet concentrates was significantly lower in the ROTEM
group, the cumulative number of platelet concentrate units
transfused was not different between groups (Table 5). In
contrast, other thromboelastometrically guided transfusion
studies have reported a significant reduction in cumulative
number of platelet concentrate units transfused.17,18,21
This discrepancy could be explained by differences
between our ROTEM algorithm and the algorithms used
in the other studies. Alternatively, our lack of difference in1122 The Journal of Thoracic and Cardiovascular Surplatelet transfusion between study groups may have been
due to the known high incidence of platelet dysfunction in
this high-risk cohort of aortic surgical patients.
Because of the aggressive intraoperative antifibrinolytic
drug regimen routinely used at our institution,26 the need
for additional tranexamic acid was negligible. Only 1 pa-
tient in the ROTEM group and 2 in the control group re-
quired additional tranexamic acid.
The major finding of this study was a significant reduc-
tion in fresh-frozen plasma transfusion in the ROTEM-
directed group. It may be postulated that similar results
could have been achieved by simply reducing fresh-frozen
plasma administration in the empirical transfusion control
group. Indeed, some experts have suggested limiting
fresh-frozen plasma transfusions during high-risk cardiac
surgery.27 Although judicious empirical blood product
transfusion may sufficiently meet transfusion requirements
in most high-risk cases, ROTEMmay still be helpful for pa-
tients with persistent microvascular bleeding by providing
a quick assessment of the entire coagulation system. More-
over, there may be advantages of the ROTEM-directed pro-
tocol that were not elucidated by the primary end point of
our study. For example, we were able to eliminate almost
completely the use of prothrombin complex concentrate,
a cost-intensive product, in the ROTEM group. We may
also conclude from our study that transfusion requirements
are highly variable between patients. For example, 15% of
patients in the ROTEM group did not require any blood
transfusion throughout the entire perioperative and postop-
erative course.
Despite the significant reduction in allogeneic blood
units used in the ROTEM-group, no increased postoperative
blood loss and no increased rate of re-exploration for post-
operative bleeding or tamponade was observed in ROTEM-
guided group (Table 5). This finding has been supported by
the results of other randomized thromboelastometric tri-
als.21,24 High re-exploration rates in both study arms
(19% and 24%) may be explained by high proportion of pa-
tients with an acute type A dissection in this study, as well as
by rigorous re-exploration strategy. Re-exploration was per-
formed expeditiously if results of coagulation tests (control
group) or ROTEM analysis (ROTEM group) were normal,
not waiting until the chest tube drainage had reached any
predefined levels. This is based on a good predictive value
of ROTEM for detection of surgical bleeding, as demon-
strated by Cammerer and colleagues.22 In our study, 4 pa-
tients in the ROTEM group who underwent re-exploration
for bleeding had normal ROTEM results, and a surgical
bleeding source was found in all cases. If bleeding persists
in the ICU despite a normal ROTEM, it is thus very likely
that this bleeding is surgical in nature. Because the results
of ROTEM analysis are available within 15 minutes, the de-
cision as to whether to take a patient back to the operating
room can be made more expeditiously.gery c November 2010
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could not find any significant difference in the clinical vari-
ables between the study arms (TableE1). There could be sev-
eral explanations for this finding. First, the blood loss and
transfusion requirements during aortic surgery with HCA
(especially acute dissection surgery) are substantial, even
when ROTEM-guided therapy is used (median blood loss
890 mL/24 h [600–1250mL]), and median allogeneic blood
used per ROTEM patient in this study 9.0 units (2.0–30.0
units). Thus even a 44% reduction in allogeneic blood trans-
fusions may not have been large enough to alleviate
transfusion-related postoperative events. Second, postopera-
tive complications after aortic surgery are likely multifacto-
rial, and transfusion-related events may be seen as only
a contributing factor to these complications. Third, and
most importantly, our study was underpowered to detect dif-
ferences in these secondary clinical outcome variables.
We found it very important to have experienced person-
nel available on a 24-hour basis in the ICU to perform the
ROTEM tests, because the use and interpretation of the RO-
TEM analyzer can be technically challenging. This was the
reason for nonenrollment of 2 elective patients and for the
divergence from ROTEM-guided algorithm in 1 other case.
Study Limitations
There are several limitations of this study. Because of the
well-known bleeding tendency in this high-risk patient pop-
ulation, our study protocol was designed to administer the
required blood products (in both study groups) simulta-
neously with protamine infusion after discontinuation of
CPB. The bias may play a role when nonblinded control
group patients were treated empirically (that is, control
group patients were transfused on the basis of clinical dis-
cretion at first), whereas ROTEM-guided patients received
the blood products solely on the basis of test results. This
is consistent with the clinical routine, however, because
the coagulation test results are usually not available in the
immediate postprotamine period. Transfusion therapy is
thus directed empirically at first to counteract the excessive
blood loss that is often encountered in these cases. This fact
underscores the advantage of ROTEM analysis, because the
test results are available before the start of weaning from
CPB. Nonetheless, we are aware that any special therapy
we implement to reduce transfusions will exert a positive
effect just by establishing a strict protocol.
We acknowledge that routine coagulation tests may be
more effective than they were in this study, provided the
time to obtain these results is shorter than in our institution.
These laboratory parameters did not really represent the he-
mostatic situation by the time they were available. The long
delay for the coagulation test results may have negatively
influenced the results in the control group. The major ad-
vantage of ROTEM is that all key parameters to guide the
transfusion are available within 15 minutes.The Journal of Thoracic and CarDivergences from the transfusion protocol were required
for 4 patients (15%) in the ROTEM group, all of whom sub-
sequently had excessive blood loss and required massive
transfusion. This undoubtedly weakened the positive results
in the ROTEM group and may explain to some extent the
lack of differences in the blood loss and in the rate of re-
exploration between the groups (Table 5). Most of these
protocol violations occurred in the early stage of this study.
These divergences became very rare as we gained more
experience with ROTEM.
In this study, we attempted to make our results generaliz-
able to this high-risk patient population by recruiting the
vast majority of consecutive aortic surgical patients oper-
ated on during the study period, including the majority of
patients undergoing emergency surgery (81% of acute
type A dissections), as well as patients receiving preopera-
tive antiplatelet or warfarin therapy. Inclusion of emergency
cases in the study raises the problem of introducing some
poorly controlled variables. Nonetheless, these are the pa-
tients who are at extremely high risk for excessive bleeding,
and they are expected to benefit most from the fast and
reliable guidance of perioperative transfusion.
In addition, heparinase-modified ROTEM may overesti-
mate the level of coagulopathy (especially platelet dysfunc-
tion) during CPB, provoking unnecessary transfusion. This
may be among the explanations for the lack of difference in
platelet transfusion between the groups.CONCLUSIONS
In conclusion, this randomized trial demonstrated that the
use of a ROTEM-guided transfusion algorithm in aortic sur-
gical patients undergoing HCAwas associated with a signif-
icant decrease in the cumulative number of transfused
allogeneic blood units. This reduction was predominantly
caused by the reduced need for fresh-frozen plasma transfu-
sion. ROTEM usagewas also independently associated with
a reduced risk of massive perioperative transfusion in these
high-risk patients. ROTEM-guided coagulation manage-
ment should be considered for all cardiac surgical patients
who are at high risk for perioperative bleeding.References
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FIGURE E1. Typical rotational thromboelastometric trace (ROTEM;
Matel Medizintechnik GmbH, Munich, Germany) with key parameters.
HEPTEM, Intrinsic activation plus heparinase neutralization thromboelas-
tometry;RT, timewhen the ROTEM-analysis has been performed;CT, clot-
ting time; CFT, clot formation time; a, alpha angle; MCF, maximal clot
firmness; A10, A15, A20, A25, A30, clot firmness (amplitude) at 10, 15,
20, 25, and 30 minutes, respectively.
FIGURE E2. Allogeneic blood units transfused during first 24 postoper-
ative hours. ROTEM, Rotational thromboelastometrically guided protocol;
RBC, red blood cell; FFP, fresh-frozen plasma; PLT, platelet concentrate;
Intraop, intraoperative; postop, postoperative.
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TABLE E1. Clinical outcome variables
Variable ROTEM (N ¼ 27) Control (N ¼ 29) P value
Time to first extubation (h, mean  SD) 127  135 113  154 .7
Reintubation (no.) 7 (26%) 5 (17%) .4
Total ventilation time (h, mean  SD) 144  139 137  172 .8
Stroke (no.) 4 (15%) 3 (10%) .6
Postoperative confusion (no.) 4 (15%) 7 (24%) .5
Dialysis-dependent renal failure (no.) 5 (19%) 7 (24%) .6
Intensive care unit stay (d, mean  SD) 7.3  9.1 8.1  8.4 .6
Intensive care unit stay>10 d (no.) 6 (22%) 7 (24%) .8
Hospital stay (d, mean  SD) 16.6  16.4 17.0  14.8 .8
In-hospital mortality (no.) 4 (15%) 5 (17%) .8
ROTEM, Thromboelastometry.
TABLE E2. Multivariate analysis of massive blood transfusion (>20 units)
Variable OR 95% CI P value
Thromboelastometrically guided protocol 0.45 0.2–0.9 0.03
Age>70 y 1.1 0.3–7.8 0.8
Preoperative aspirin 1.9 0.5–8.5 0.5
Circulatory arrest>30 min 2.6 0.7–11.5 0.3
Reoperation 3.4 0.6–17.8 0.3
Acute type A dissection 3.9 1.9–11.7 0.03
Preoperative creatinine>1.5 mg/dL 6.2 0.9–15.2 0.1
Cardiopulmonary bypass time>200 min 7.9 1.2–35.1 0.03
Preoperative hematocrit<30% 15.1 1.9–65.3 0.02
OR, Odds ratio; CI, confidence interval.
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